VT3989 continues to show promising early results in patients with advanced mesothelioma

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor ...
Business Insider

Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and ...

VQ-101 is the first small molecule to demonstrate >70% activation of the lysosomal enzyme glucocerebrosidase (GCase) in GBA-Parkinson’s (GBA-PD) patients In the ongoing Phase 1b study in patients with ...
Business Wire

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the ...
usace.army.mil

U.S. Army Taps Three Companies for Cutting-Edge Launched Effects Demonstration

Redstone Arsenal, Ala. 27 March 2025. The US Army has selected three companies for a special demonstration of the Launched Effects-Short Range (LE-SR) system, a key step towards fielding this ...